BPC-157 is not FDA-approved. The current 503A regulation and interim categories do not establish an ordinary retail bulk-compounding route [9] [5]. FDA’s July briefing reports no approved product in its international search; that attributed finding is different from a current independent check of every country.
No: BPC-157 is not FDA-approved
BPC-157 has never been approved as a drug by FDA. FDA's review found no approved product containing it in any country, and no listing for it in the European, Japanese or International Pharmacopoeias [2]. BPC-157 is a common name, not an official drug name, and FDA has found different substances sold under it.
It is a 15-amino-acid peptide, first described in 1993 as a fragment of a protein found in gastric juice [2]. Almost all of its supporting research is in animals. The size of the human record, and what it means for safety, is on whether BPC-157 is safe.
Current records do not establish routine bulk-compounding eligibility
No. A 503A pharmacy may compound from a bulk ingredient only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [4]. FDA's July 2026 briefing says BPC-157 meets none of these: there is no monograph, and it is not a component of any approved drug [2]. It is not on the bulks list or in Category 1 of FDA's 503A nominations [5].
The reviewed 503B nomination document does not identify BPC-157 [6]. That document describes interim categories, not a product approval. A particular commercial offer still needs an applicable legal basis; a facility’s registration alone cannot provide it.
| Version | FDA-approved? | Who makes it | Legal path | What it means for you |
|---|---|---|---|---|
| Approved drug | None identified by FDA’s July 2026review | No one | None | There is no approved BPC-157 to prescribe |
| Compounded, 503A pharmacy | No | No routine bulk eligibility established | None: no monograph, no approved-drug component, not on the bulks list | A prescription alone does not establish a compounding exemption |
| Compounded, 503B outsourcing facility | No | Not listed | Not identified in the reviewed 503B nomination categories | A nomination list is not drugapproval or a complete assessment of every legalcondition |
| Dietary-supplement capsules and tablets | No | Supplement marketers | Marketed, per FDA; not approved | Not reviewed by FDA as a drug |
| "Research use only" vials | No | Unregulated sellers | Not for human use | Contents unchecked; FDA found different substances sold under the name |
Status as of this update, from FDA's July 2026 briefing, its 503A and 503B lists and its 503A compounding page.
What leaving Category 2 in April 2026 actually meant
FDA’s current safety page lists BPC-157 under withdrawn nominations rather than its current Category 2 table [7]. Withdrawal does not establish approval, product quality or a new commercial exemption.
Withdrawal from an interim category does not add BPC-157 to the current 503A regulation or Category 1 list [9] [5]. Avoid treating a change in nomination status as a product approval or a safety finding.
| Date | What happened |
|---|---|
| May 14, 2026categories | BPC-157 is not in Category 1; withdrawn nominations do not confer approval [5] |
| July 2026briefing | FDA reviewers weigh against listing the nominated BPC substances [2] |
| Current 503A regulation | Section 216.23 lists six substances; BPC-157 is absent [9] |
| October 2026 OIRA entry | Peptide access notice pending review; not issued policy [1] |
The July 2026 advisory committee: advice, not a decision
FDA's own reviewers recommended against listing BPC-157. Their briefing concluded that "a balancing of the criteria weighs against" both forms of BPC-157, citing poor chemical characterization, little safety information, immunogenicity risk and insufficient evidence for ulcerative colitis, a disease with approved treatments [2].
FDA’s meeting page explains that advisory recommendations are nonbinding [3]. The current 503Aregulation still does not list BPC-157 [9]. OIRA’s peptide-policy entry is pending review; the entry does not publish an issued policy, its terms or a product approval [1].
| Claim | What the record shows | Verdict |
|---|---|---|
| "FDA approved BPC-157 in 2026" | No approval exists anywhere [2] | False |
| "BPC-157 is still in Category 2" | It left Category 2 in April 2026 after the nominations were withdrawn [7] | Out of date |
| "It's now legal to compound" | Still no monograph, no approved-drug component and no bulks-list place [2] | False |
| "The committee vote made it legal" | Advisory recommendations are nonbinding; the current 503Aregulation still excludes BPC-157 [9] | False |
What about BPC-157 sold as a supplement or for "research use only"?
FDA's briefing notes BPC-157 is marketed in the US as an ingredient in dietary-supplement capsules and tablets. That is a marketing fact, not an FDA approval, and there is no USP dietary-supplement monograph for it [2]. A "research use only" label means the product is not intended for people. FDA's review also warns that different substances are sold under the BPC-157 name, so a buyer may not get what the label says [2].
Are BPC-157 and TB-500 FDA-approved? Neither one
The TB-500 guide addresses a separate unapproved peptide. Full-length thymosin beta-4 and its fragment are different molecules; studies of one cannot establish the other’s safety or efficacy. A mixture also cannot identify which component caused an observed result. FDA’s current safety table separately names the fragment and BPC-157 [7].
The TB-500 guide addresses a separate unapproved peptide. Full-length thymosin beta-4 and its fragment are different molecules; studies of one cannot establish the other’s safety or efficacy. A mixture also cannot identify which component caused an observed result. FDA’s current safety table separately names the fragment and BPC-157 [7].
What this means for you
The current records do not establish an ordinary retail bulk-compounding route. This is distinct from appropriately authorized research; neither a clinic’s prescription nor a ClinicalTrials.gov entry alone proves every applicable requirement has been met [10]. See legal access and the route-specific evidence.
What to ask a clinician instead
Most people look at BPC-157 for an injury, joint pain or a gut problem. Each of those has approved treatments, and FDA noted several for ulcerative colitis in its review [2]. Questions worth asking:
- What is causing my symptoms, and which FDA-approved treatments fit?
- Is there a registered clinical trial I could qualify for?
- If someone offers me BPC-157, how would I know what is actually in it?
How we read regulatory status, and why we never list sellers of non-compoundable peptides, is explained on how we check.
Research authorization differs from retail access
FDA’s IND framework separates investigational use from commercial marketing. It describes review of nonclinical safety, manufacturing and stability information, the clinical protocol, investigator qualifications, informed consent and ethics oversight [10]. A study record or the words “research use only” do not establish those requirements have been met.
The current registry includes an oral-gummy study marked completed with 40 actual participants over 8 weeks, but with no results posted and retrospective registration [11]. It demonstrates why “no human oral study exists” is too broad. It does not establish a clinical benefit, FDA approval, lawful retail availability or authorization of any other seller’s product.
For athletes, the exact 2026 WADA list names BPC-157 in S0, prohibited at all times [8]. That sports rule is a separate question from drugapproval, clinical benefit and permission to participate in a research study.